(Q46591786)

English

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

scientific article published in July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

1 reference

based on heuristic

inferred from title

author name string

N L Dovlatova

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

J A Jakubowski

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

A Sugidachi

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

S Heptinstall

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

publication date

1 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

1153-1159

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

The role of ADP receptors in platelet function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Platelet P2 receptors: old and new targets for antithrombotic drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Structure and stereochemistry of the active metabolite of clopidogrel

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2008.03020.X

21 January 2018

Identifiers

10.1111/J.1538-7836.2008.03020.X

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18485086

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46591786&oldid=2121199537"